| Name |
Jean Clairambault |
| Country |
France |
| Email |
jean.clairambault@inria.fr |
| Co-Author(s) |
Rebecca Chisholm, Jean Clairambault , Alexandre Escargueil, Tommaso Lorenzi, Alexander Lorz, Benoit Perthame, Emmanuel Trelat |
| Submit Time |
2014-02-05 08:48:22 |
Session |
Special Session 66: Deterministic and stochastic models in biology and medicine
|
|
| Contents |
| Considering cancer as an evolutionary disease, we aim at understanding the means
by which cancer cell populations develop resistance mechanisms to drug therapies, in order to circumvent them by using optimised therapeutic combinations. Rather than focusing on molecular mechanisms such as overexpression of intracellular drug processing enzymes or ABC transporters that are responsible for resistance at the individual cell level, we propose to introduce abstract phenotypes (that nevertheless may be experimentally identified and controlled in cell cultures, according to the drug and to the cell line at stake) of resistance structuring cancer cell populations. The models we propose rely on continuous adaptive dynamics of cell populations, and are amenable to predict evolution of these populations with respect to the phenotypic traits of interest.
According to the cell populations at stake and to the exerted drug pressure, is drug resistance in cancer a permanently acquired phenotypic trait or is it reversible? Can it be avoided or overcome by rationally (model-guided) designed combinations of drugs (to be optimised)? These are some of the questions we will try to answer in a collaboration between a team of mathematicians and another one of biologists, both dealing with cancer and Darwinian evolution of cell populations. |
|